CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Arms / Cohorts
Experimental, Arm D:Part 2: BMS-986393 + Elranatamab
Not Evaluated
Not yet accepting
Experimental, Arm C:Part 2: BMS-986393 + Iberdomide
Not Evaluated
Not yet accepting
Experimental, Arm B:Part 1: BMS-986393 + Mezigdomide
Not Evaluated
Accepting patients
Experimental, Arm B:Part 2: BMS-986393 + Mezigdomide
Not Evaluated
Not yet accepting
Experimental, Arm C:Part 1: BMS-986393 + Iberdomide
Not Evaluated
Accepting patients
Experimental:Arm E: BMS-986393 + Mezigdomide and Dexamethasone
Not Evaluated
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.